TY  - GEN
AU  - Ferenci,Peter
AU  - Bourgeois,Stefan
AU  - Buggisch,Peter
AU  - Norris,Suzanne
AU  - Curescu,Manuela
AU  - Larrey,Dominique
AU  - Marra,Fiona
AU  - Kleine,Henning
AU  - Dorr,Patrick
AU  - Charafeddine,Mariem
AU  - Crown,Eric
AU  - Bondin,Mark
AU  - Back,David
AU  - Flisiak,Robert
TI  - Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
SN  - 1365-2893
PY  - 2020///0722
KW  - 2-Naphthylamine
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Anilides
KW  - therapeutic use
KW  - Antiviral Agents
KW  - Carbamates
KW  - Cyclopropanes
KW  - Drug Interactions
KW  - Drug Therapy, Combination
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - drug effects
KW  - Hepatitis C, Chronic
KW  - drug therapy
KW  - Humans
KW  - Internationality
KW  - Lactams, Macrocyclic
KW  - Macrocyclic Compounds
KW  - Male
KW  - Middle Aged
KW  - Proline
KW  - analogs & derivatives
KW  - Prospective Studies
KW  - Ribavirin
KW  - Ritonavir
KW  - Sulfonamides
KW  - Sustained Virologic Response
KW  - Uracil
KW  - Valine
KW  - Young Adult
N1  - Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/jvh.13080
ER  -